Insulet Corporation
Insulet Corporation, founded in 2000, develops tubeless wearable insulin delivery systems, including Omnipod 5, an automated system controlled by a smartphone, serving over 600,000 customers in 25 countries.
Insulet Corporation, founded in 2000 and listed on NASDAQ as PODD, develops tubeless, wearable automated insulin delivery systems for diabetes management. Its Omnipod platform, originally conceived as a napkin sketch, has grown over two decades into a global drug-delivery system serving more than 600,000 customers across 25 countries. The company reported annual revenue of $2.1 billion.
The flagship product, Omnipod 5, is the world's first tubeless automated insulin delivery system controlled by a smartphone and the most prescribed automated insulin delivery system in the United States. Insulet's technical work spans medical devices, wearable drug delivery, automated insulin delivery (AID), and smartphone-controlled device software. The company operates in North America, Europe, the Middle East and Asia Pacific.
Insulet describes its origins in a personal mission: a father seeking to spare his son daily insulin injections. The firm states a purpose of making diabetes a smaller part of life through simplicity, freedom and healthier outcomes, and refers to its customer community as "Podders". It cites purpose-driven innovation and a commitment to sustainable, responsible growth as operating principles.